TrialThe Lancet. Infectious diseases2026

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

Rodney Dawson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.